Finepoint Capital LP Grows Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Finepoint Capital LP grew its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 57.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,111,104 shares of the company's stock after acquiring an additional 403,700 shares during the quarter. EyePoint Pharmaceuticals accounts for 0.5% of Finepoint Capital LP's portfolio, making the stock its 17th biggest holding. Finepoint Capital LP owned about 1.63% of EyePoint Pharmaceuticals worth $8,278,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. KLP Kapitalforvaltning AS purchased a new stake in EyePoint Pharmaceuticals during the 4th quarter valued at about $59,000. AlphaQuest LLC lifted its stake in shares of EyePoint Pharmaceuticals by 13,246.6% in the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company's stock worth $73,000 after buying an additional 9,670 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of EyePoint Pharmaceuticals during the fourth quarter valued at approximately $76,000. China Universal Asset Management Co. Ltd. increased its position in shares of EyePoint Pharmaceuticals by 40.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company's stock valued at $108,000 after acquiring an additional 4,179 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in EyePoint Pharmaceuticals by 22.4% in the 4th quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company's stock worth $113,000 after acquiring an additional 2,782 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on EYPT. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Chardan Capital reiterated a "buy" rating and issued a $33.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Citigroup started coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, EyePoint Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $26.63.

EyePoint Pharmaceuticals Trading Up 4.2 %

NASDAQ EYPT traded up $0.20 during trading hours on Friday, hitting $5.00. 240,324 shares of the company's stock traded hands, compared to its average volume of 854,894. EyePoint Pharmaceuticals, Inc. has a 52 week low of $3.91 and a 52 week high of $23.65. The firm has a market capitalization of $343.65 million, a P/E ratio of -2.50 and a beta of 1.39. The business's fifty day moving average price is $6.08 and its two-hundred day moving average price is $7.93.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10). The company had revenue of $11.60 million during the quarter, compared to analysts' expectations of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. On average, sell-side analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.